Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is making significant strides in the development of a novel class of DNA Damage Response (DDR) therapies aimed at hard-to-treat cancers. The company recently announced a key manufacturing milestone: successful advancement toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010. This scale-up is critical for preclinical and clinical development, enabling the company to produce sufficient quantities for toxicology studies and eventual clinical trials.
The company's approach targets Polynucleotide Kinase Phosphatase (PNKP), an enzyme that plays a crucial role in repairing DNA damage. By inhibiting PNKP, Onco-Innovations aims to disrupt cancer cells' ability to repair DNA damage, leading to their death. This strategy is particularly relevant for cancers that exhibit defective DNA repair pathways, as these tumors often rely on alternative repair mechanisms like PNKP to survive conventional therapies such as radiation and certain chemotherapies.
In addition to the manufacturing milestone, Onco-Innovations signed a Letter of Intent with Nanosoft Polymers to support polymer development, drug delivery optimization, and formulation work for the ONC010 program. This collaboration is expected to enhance the drug's bioavailability and targeting, potentially improving therapeutic outcomes. The partnership underscores the company's commitment to advancing its pipeline through strategic alliances.
The importance of this announcement lies in the potential of PNKP inhibitors to address a significant unmet medical need. Many cancers, including breast, ovarian, and pancreatic cancers, often harbor defects in DNA repair pathways, making them vulnerable to therapies that further impair DNA repair. Onco-Innovations' focus on PNKP could offer a new treatment option for patients who have limited alternatives. The company's progress in manufacturing and formulation development suggests it is moving closer to clinical testing, which could validate this novel approach.
For more information, visit the company's newsroom at ibn.fm/ONNVF or the BioMedWire website for full disclaimers and terms of use at https://www.BioMedWire.com/Disclaimer.
